Loading...
Market
How many patients will be treated with 4DMT's 4D-150 gene therapy for wet-AMD in the first year of approval?
2
Resolution / Starting Odds
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
4DMT sales reports and healthcare data
Story
4D Molecular Announces Positive Results for 4D-150 Wet-AMD Gene Therapy
Sep 18, 2024, 08:08 PM
4D Molecular Therapeutics (4DMT) has announced positive results in the development of a gene therapy for wet age-related macular degeneration (wet-AMD), a leading cause of age-related blindness. The therapy, known as 4D-150, has shown robust and durable clinical activity. Notably, only two out of 71 dosed patients have exhibited signs of ocular inflammation. The company has also outlined the design for its upcoming Phase 3 program, known as 4FRONT, during the 4D-150 Wet AMD Development Day. This progress highlights the ongoing advancements in gene therapy, particularly in treatments for common conditions like wet-AMD.
View original story
Similar markets
Less than 100 patients • 25%
100 to 500 patients • 25%
501 to 1000 patients • 25%
More than 1000 patients • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Yes • 50%
No • 50%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
0-10 patients • 25%
11-20 patients • 25%
21-30 patients • 25%
More than 30 patients • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Yes • 50%
No • 50%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 100 • 25%
100 to 500 • 25%
500 to 1000 • 25%
More than 1000 • 25%